Shots:

• The P-III study (MAIA) evaluating Darzalex + lenalidomide and dexamethasone (D-Rd) vs Rd alone in 737 patients with MM
• The post-hoc subgroup analysis from the 3 age groups incl. patients ≤75yrs./≤70yrs./ b/w 70 & 75yrs. showed m-PFS (not reached vs 37.5mos.)/ (not reached vs 39.2mos.)/ (61.9mos. vs 37.5mos.); MRD-negativity (36.1% vs 12.0%)/ (35.9% vs 11.7%)/ (36.2% vs 12.2%); ORR (95.2% vs 81.7%)/ (93.6% vs 80.5%)/ (96.2% vs 82.4%), respectively
• In 2nd analysis, patients aged ≥75 with high cytogenetic risk/Gain(1q21) or Amp(1q21) showed m-PFS (45.3mos. vs 29.6mos.)/ (53.2mos. vs 32.3mos.); MRD-negativity (25.0% vs 2.3%)/ (33.1% vs 11.7%); ORR (91.7% vs 75%)/ (95.3% vs 85%), rates of grade 3/4 & serious TEAEs were similar in both groups with a lower rate of discontinuation due to TEAEs

Ref: PRNewswire | Image: Janssen